Abstracts
PCN28 RETROSPECTIVE CLAIMS DATABASE ANALYSIS OF THE DIRECT MEDICAL COSTS ASSOCIATED WITH SORAFENIB AND SUNITINIB IN THE TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA WHO ARE UNDER 65 YEARS OLD
Quinn DI Q 1 , Barghout V 2 , Moyneur E 3 1 University of Southern California, Los Angeles, CA, USA, 2 Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 3 StatLog Consulting Inc, L'Ange-Gardien, QC, Canada OBJECTIVES: To quantify direct medical costs (inpatient, outpatient, pharmacy) of initial therapy with FDA-approved renal cell carcinoma (RCC) oral therapies (sorafenib, sunitinib) in treatment of RCC patients who are privately insured and under 65 years. METHODS: Using data from MarketScan MedStat, a database covering all US census regions and included 18 million lives, we conducted a retrospective claims-based study. Between January 2002 and December 2007, patients with 2 RCC claims (ICD-9 189.0, 198.0), continuous health care coverage, and 180 days of coverage before RCC diagnosis and who received sorafenib or sunitinib were eligible for inclusion. Observation period lasted from fi rst drug-dispensing date until 12 months or fi rst of therapy-switch, nephrectomy, disenrollment, or study end (December 31, 2007) . Univariate and multivariate Tobit analyses were conducted. Variables included age, sex, region, plan type, comorbidities, prior treatments/procedures, and time since RCC diagnosis. RESULTS: Of 10,462 RCC patients identifi ed, 144 received sorafenib and 220 received sunitinib as initial therapy. In the 180 days before RCC diagnosis, total direct medical costs, baseline demographics, and comorbidities were not statistically signifi cantly different between groups. Univariate total monthly medical costs for the sunitinib group were statistically signifi cantly greater than for the sorafenib group ($9476 vs. $7426, respectively; P 0.01), representing a yearly cost difference for sunitinib of $24,588 more than sorafenib. Univariate incremental monthly inpatient and pharmacy costs for sunitinib were $861 (P 0.01) and $889 (P 0.01), respectively, and outpatient therapy was $300 (P 0.14) more than sorafenib. Multivariate analyses for incremental total monthly inpatient and pharmacy costs for sunitinib also remained signifi cant at $1399, $1259, and $689, respectively (P 0.01). CONCLUSIONS: This analysis showed statistically signifi cant cost differences, including lower total monthly medical, inpatient and pharmacy costs, associated with sorafenib compared with sunitinib when used as initial therapy in RCC patients under 65 years. Reasons for these differences require further exploration.
PCN29 THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES
Nuijten M j 1 , Chouaid C 2 , Vergnenegre A 3 1 Ars Accessus Medica, Jisp, Netherlands, 2 Hôpital Saint-Antoine, Paris, France, 3 CHU Limoges, Limoges, France OBJECTIVES: New therapies for advanced NSCLC offering benefi ts over standard treatment with chemotherapy should also offer value for money. Bevacizumab combined with chemotherapy improves survival in patients with advanced NSCLC compared with chemotherapy alone. Cetuximab has shown a marginal survival benefi t but no improvement in progression-free survival. Marketing authorization is anticipated in 2009. This study aimed to compare treatment costs of bevacizumab-based or cetuximab-based therapy in France, Germany, Italy and Spain. METHODS: A Markov model was used to compare drug and administration costs associated with treating advanced NSCLC with bevacizumab-based or cetuximabbased therapy. The model assumes patients move from non-progressive to progressed disease before death, according to transition probabilities of the effi cacy of bevacizumab-based and cetuximab-based therapy in terms of progression-free survival using data from the respective pivotal trials. A common post-progression survival risk was assumed. Drug costs assumed up to 6 chemotherapy cycles, initial administration of cetuximab at 400 mg/m² followed by 250 mg/m² weekly until progression and that bevacizumab was administered at 7.5 mg/kg until progression. The model estimated average drug and administration costs (data derived from local sources) per patient for either treatment. RESULTS: Across the four countries the average monthly drug cost with bevacizumab-based therapy ranged from €130 to €902 less per patient compared with cetuximab-based therapy. Similarly, the mean total treatment cost with bevacizumab-based therapy ranged from €4,713 to €12,269 less per patient compared with cetuximab-based therapy across the four countries. For example, in France mean treatment costs for bevacizumab-based and cetuximab-based therapy were €23,849 and €35,678, respectively (a saving of €11,829 per patient with bevacizumab-based therapy). CONCLUSIONS: Targeted therapy using bevacizumab is less costly than cetuximab in representative countries. Based on these results bevacizumab provides better value in terms of budget and outcomes in patients with advanced NSCLC.
PCN30 THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
Nuijten M j Ars Accessus Medica, Jisp, Netherlands OBJECTIVES: Although new treatments for advanced NSCLC offer benefi ts over standard chemotherapy they should also offer value for money. Bevacizumab improves survival and time to progression in patients with advanced NSCLC with chemotherapy compared with chemotherapy alone. Pemetrexed has shown improved effi cacy over gemcitabine for induction chemotherapy and best supportive care in maintenance and marketing authorization is anticipated during 2009. The aim of this study was to compare the treatment costs of bevacizumab plus cisplatin and gemcitabine (bevacizumab-based therapy) with pemetrexed plus cisplatin induction and maintenance therapy (pemetrexed-based therapy) in Germany and Italy. METHODS: A 3-state Markov model was used to evaluate the costs of treating advanced or recurrent NSCLC with either bevacizumab-based or pemetrexed-based therapy. The model assumes patients move between states according to transition probabilities derived from the effi cacy data (progression-free survival) from the pivotal trials. Drug costs assumed chemotherapy was given for up to 4 cycles, but that single agents pemetrexed and bevacizumab (7.5 mg/kg) were administered until progression. RESULTS: Compared with pemetrexed-based therapy, the mean monthly drug cost with bevacizumabbased therapy was €769 less per patient in Italy. The mean monthly drug costs for bevacizumab-based therapy were €6455 and €6106 for pemetrexed-based therapy in Germany. However, the mean monthly cost of bevacizumab was always less than pemetrexed (€3499 vs €5871 in Germany; €2067 vs €3600 in Italy). The mean total treatment cost with bevacizumab-based therapy was always less than pemetrexedbased therapy (e.g. €27530 for bevacizumab-based therapy, €33291 for pemetrexedbased therapy in Italy). CONCLUSIONS: Triplet therapy with bevacizumab is similar or less costly than doublet therapy with pemetrexed. Furthermore, it is anticipated that drug costs with bevacizumab-based therapy will reduce in 2009 when gemcitabine comes off patent. From a budget perspective bevacizumab should be considered as the targeted therapy of choice for patients with advanced NSCLC.
